ClinicalTrials.gg
Active, not recruitingNCT06959225Updated Nov 12, 2026

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

A Phase 3 interventional study of Ruxolitinib Cream and Vehicle Cream in Hidradenitis Suppurativa, sponsored by Incyte Corporation. Active, not recruiting at 101 sites in 8 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Updated Nov 12, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
580
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.

Enrollment
5th of 12
580 · median 391
Started
2025
with 3 others
Phase 3
6 of 12
1 open now
Registered
10th of 12
by date

Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one is the 5th largest by enrollment, is one of 4 that started in 2025, is one of 6 in phase 3, and was the 10th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hidradenitis Suppurativa by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis suppurativa
  • skin disease
  • ruxolitinb cream
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of HS for at least 6 months prior to screening visit.
  • Mild to moderate HS (Hurley I or II) with the following at both screening and baseline visits:

    • A total AN count of at least 4, with no draining tunnels AND
    • Affecting at least 2 distinct anatomical areas
  • Agreement to NOT use topical and systemic antibiotics for treatment of HS during the vehicle-controlled period.
  • Agreement to NOT use topical antiseptics, including washes and leave-on products on the areas affected by HS lesions during the vehicle-controlled period and Weeks 16 to 20 of the extension period.
  • Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Body surface areas to be treated exceed 20% BSA at screening or baseline
  • Presence of draining tunnels at screening or baseline.
  • Medical history including current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
  • Laboratory values outside of the protocol-defined criteria.
  • Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.
  • Further exclusion criteria apply.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
580 participants (actual)

Study arms

  • Experimental
    Ruxolitinib 1.5 % Cream

    Participants received ruxolitinib 1.5% cream, applied topically to the affected area as defined in the protocol.

    Drug: Ruxolitinib Cream

  • Placebo comparator
    Vehicle Cream

    Participants received vehicle cream, applied topically to the affected area as defined by the protocol.

    Drug: Vehicle Cream

Interventions

  • Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

  • DrugVehicle Cream

    Matching vehicle cream applied topically to the affected area as a thin film twice daily.

06

What researchers measure

Primary outcomes

  1. Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baseline

    HiSCR75 is defined as at least a 75% reduction from baseline in the total abscess and/or inflammatory nodule (AN) count with no increase from baseline in abscess or draining tunnel count.

    Time frame: Week 16

Secondary outcomes

  1. Proportion of participants with ≥ 1 flare

    Defined as a ≥ 25% increase in AN count with a minimum increase in total AN count of 2 relative to baseline.

    Time frame: Up to 16 weeks

  2. Proportion of participants who achieve HiSCR50

    Defined as a ≥ 50 reduction from baseline in total AN count with no increase from baseline in abscess or draining tunnel count.

    Time frame: Week 16

  3. Proportion of participants who achieve Skin Pain Numeric Rating Scale (NRS)3 among participants with baseline Skin Pain NRS score ≥ 3

    Participants with a Skin Pain score of at least 3 at baseline and who achieve Skin Pain NRS3, defined as at least 3-unit reduction from baseline in the Skin Pain NRS.

    Time frame: Week 16

  4. Treatment-IR Population: Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) from baseline

    Treatment IR-Population defined as participants who had an inadequate response, intolerance, or contraindication to prior topical or systemic medications for HS. HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count with no increase from baseline in abscess or draining tunnel count.

    Time frame: Week 16

  5. Treatment-IR Population: Proportion of participants with ≥ 1 HS flare

    Defined as a ≥ 25% increase in total AN count with a minimum increase in AN count of 2 relative to baseline.

    Time frame: Up to 16 weeks

  6. Treatment-IR Population: Proportion of participants who achieve Skin Pain Numeric Rating Scale (NRS)3 among participants with baseline Skin Pain NRS score ≥ 3

    Participants with a Skin Pain score of at least 3 at baseline and who achieve Skin Pain NRS3, defined as at least 3-unit reduction from baseline in the Skin Pain NRS.

    Time frame: Week 16

  7. Proportion of participants who achieve HiSCR50/75/90/100 at each postbaseline visit

    Defined as a ≥ 50%/75%/90%/100% reduction from baseline in total AN count with no increase from baseline in abscess or draining tunnel count.

    Time frame: Up to 16 weeks

  8. Extension Period: Proportion of participants with ≥ 1 HS flare

    Defined as a ≥ 25% increase in total AN count with a minimum increase in AN count of 2 relative to baseline.

    Time frame: From Week 16 through Week 52

  9. Proportion of participants who achieve abscess and/or inflammatory nodule (AN)75 at each postbaseline visit

    Defined as a ≥ 75% reduction from baseline in total AN count.

    Time frame: Up to 52 weeks

  10. Mean change from baseline in total AN count at each postbaseline visit

    Defined as mean change in total AN count.

    Time frame: Up to 52 weeks

  11. Percentage change from baseline in total AN count at each postbaseline visit

    Defined as percent change from baseline in total AN count.

    Time frame: Up to 52 weeks

  12. Mean change from baseline in abscess count at each postbaseline visit

    Defined as mean change of abscess(es) count relative to baseline.

    Time frame: Up to 52 weeks

  13. Percentage change from baseline in abscess count at each postbaseline visit

    Percent Change from baseline in number of abscess(es).

    Time frame: Up to 52 weeks

  14. Mean change from baseline in inflammatory nodule count at each postbaseline visit

    Defined as mean change of inflammatory nodule count relative to baseline.

    Time frame: Up to 52 weeks

  15. Percentage change from baseline in inflammatory nodule count at each postbaseline visit

    Defined as percent change from baseline in number of inflammatory nodule(s).

    Time frame: Up to 52 weeks

  16. Proportion of participants with presence of draining tunnels at each postbaseline visit

    Participants with presence of draining tunnels.

    Time frame: Up to 52 weeks

  17. Proportion of participants who achieve Skin Pain Numeric Rating Scale (NRS)3 among participants with baseline Skin Pain NRS score ≥ 3 at each postbaseline visit

    Participants with a Skin Pain score of at least 3 at baseline and who achieve Skin Pain NRS3, defined as at least 3-unit reduction from baseline in the Skin Pain NRS.

    Time frame: Up to 52 weeks

  18. Proportion of participants who achieve Itch Numeric Rating Scale (NRS)30 among participants with baseline Itch NRS score ≥ 3 at each postbaseline visit

    Participants with a Itch score of at least 3 at baseline and who achieve Itch NRS30, defined as at least a 30% reduction and at least 1-unit reduction from baseline in the Itch NRS.

    Time frame: Up to 52 weeks

  19. Proportion of participants who achieve Patient Global Impression of Change (PGIC) at each postbaseline visit

    The PGIC is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.

    Time frame: Up to 52 weeks

  20. Proportion of participants who achieve PGIC score 1 or 2 at each postbaseline visit

    The PGIC is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.

    Time frame: Up to 52 weeks

  21. Patient Global Impression of Severity (PGIS) score at each postbaseline visit

    The PGIS is a single-item, self-reporting measure in which the participant rates the severity of their overall status over the past week based on a 5-point scale: (1) none, (2) mild, (3) moderate, (4) severe, and (5) very severe.

    Time frame: Up to 52 weeks

  22. Change from baseline in PGIS Score at each postbaseline visit

    The PGIS is a single-item, self-reporting measure in which the participant rates the severity of their overall status over the past week based on 5-point scale: (1) none, (2) mild, (3) moderate, (4) severe, and (5) very severe.

    Time frame: Up to 52 weeks

  23. Proportion of participants who achieve status of Dermatology Life Quality Index (DLQ1)4 at each postbaseline visit

    Defined as a ≥ 4-point reduction in DLQI score relative to baseline. The DLQI is a simple, 10-question, validated questionnaire to measure how much a skin problem has affected an adult participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment.

    Time frame: Up to 52 weeks

  24. Proportion of participants who achieve status of Children's Dermatology Life Quality Index (CDLQ1)6 at each postbaseline visit

    Defined as a ≥ 6-point reduction in CDLQI score relative to baseline. The CDLQI is a 10-question, validated questionnaire to measure the impact of skin disease on the lives of children over the previous 7 days.

    Time frame: Up to 52 weeks

  25. Change from baseline in Hidradenitis Suppurativa Quality of Life (HiSQoL) score at each postbaseline visit

    The HiSQoL is a 17-item, HS-specific, health-related, quality-of-life instrument with a 7-day recall period used to assess HS symptoms and the impact of HS problems on quality of life.

    Time frame: Up to 52 weeks

  26. Percent change from baseline in Hidradenitis Suppurativa Quality of Life (HiSQoL) score at each postbaseline visit

    The HiSQoL is a 17-item, HS-specific, health-related, quality-of-life instrument with a 7-day recall period used to assess HS symptoms and the impact of HS problems on quality of life.

    Time frame: Up to 52 weeks

  27. Change from baseline in Hidradenitis Suppurativa Quality of Life - Adolescent (HiSQoL-AA) at each postbaseline visit

    The HiSQoL-AA is a 15-item instrument with a 7-day recall period used to assess HS symptoms and experiences of HS in adolescent.

    Time frame: Up to 52 weeks

  28. Percent change from baseline in Hidradenitis Suppurativa Quality of Life - Adolescent (HiSQoL-AA) at each postbaseline visit

    he HiSQoL-AA is a 15-item instrument with a 7-day recall period used to assess HS symptoms and experiences of HS in adolescent.

    Time frame: Up to 52 weeks

  29. Change from baseline in EuroQol 5-dimension 5-level scale (EQ-5D-5L) score at each postbaseline visit

    The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome.

    Time frame: Up to 52 weeks

  30. Treatment-IR Population: Change from baseline in total abscess count at each postbaseline visit

    Defined as change from baseline in total abscess count.

    Time frame: Up to 52 weeks

  31. Treatment-IR Population: Percent change from baseline in total abscess count at each postbaseline visit

    Percent Change from baseline in total abscess count.

    Time frame: Up to 52 weeks

  32. Treatment-IR Population: Change from baseline in total inflammatory nodule count at each postbaseline visit

    Defined as change from baseline in total number of inflammatory nodule(s).

    Time frame: Up to 52 weeks

  33. Treatment-IR Population: Percent change from baseline in total inflammatory nodule count at each postbaseline visit

    Defined as percent change from baseline in number of inflammatory nodule(s).

    Time frame: Up to 52 weeks

  34. Treatment-IR Population: Proportion of participants with presence of draining tunnels at each postbaseline visit

    Participants with presence of draining tunnels.

    Time frame: Up to 52 weeks

  35. Number of Treatment Emergent Adverse Events (TEAEs)

    A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first application of study cream.

    Time frame: Up to 56 weeks

07

Study locations

101 sites
  • Investigative Site US020
    Phoenix, Arizona 85008, United States
  • Investigative Site US033
    Scottsdale, Arizona 85259, United States
  • Investigative Site US054
    Tempe, Arizona 85282, United States
  • Investigative Site US002
    Fayetteville, Arkansas 72703, United States
  • Investigative Site US055
    Brea, California 92821, United States
  • Investigative Site US004
    Laguna Niguel, California 92677, United States
  • Investigative Site US007
    Los Angeles, California 90033, United States
  • Investigative Site US013
    San Diego, California 92103, United States
  • Investigative Site US060
    San Diego, California 92120, United States
  • Investigative Site US038
    San Diego, California 92121, United States
  • Investigative Site US059
    Aurora, Colorado 80045, United States
  • Investigative Site US045
    Boynton Beach, Florida 33437, United States
  • Investigative Site US028
    Fort Myers, Florida 33912, United States
  • Investigative Site US016
    Miami, Florida 33142, United States
  • Investigative Site US027
    Sanford, Florida 32771, United States
  • Investigative Site US057
    Sweetwater, Florida 33172, United States
  • Investigative Site US029
    Tampa, Florida 33609, United States
  • Investigative Site US061
    Atlanta, Georgia 30322, United States
  • Investigative Site US053
    Atlanta, Georgia 30331, United States
  • Investigative Site US019
    Marietta, Georgia 30060, United States
  • Investigative Site US026
    Chicago, Illinois 60657, United States
  • Investigative Site US049
    Clarksville, Indiana 47129, United States
  • Investigative Site US052
    West Lafayette, Indiana 47906, United States
  • Investigative Site US001
    Bowling Green, Kentucky 42104, United States
  • Investigative Site US022
    Louisville, Kentucky 40241, United States
  • Investigative Site US050
    Baton Rouge, Louisiana 70809, United States
  • Investigative Site US046
    Glenn Dale, Maryland 20769, United States
  • Investigative Site US003
    Boston, Massachusetts 02115, United States
  • Investigative Site US030
    Boston, Massachusetts 02215, United States
  • Investigative Site US010
    Quincy, Massachusetts 02169, United States
  • Investigative Site US051
    Novi, Michigan 48377, United States
  • Investigative Site US006
    Minneapolis, Minnesota 55455, United States
  • Investigative Site US021
    New Brighton, Minnesota 55112, United States
  • Investigative Site US036
    Saint Joseph, Missouri 64506, United States
  • Investigative Site US034
    New City, New York 10956, United States
  • Investigative Site US018
    New York, New York 10003, United States
  • Investigative Site US017
    New York, New York 10023, United States
  • Investigative Site US023
    Rochester, New York 14623, United States
  • Investigative Site US014
    Chapel Hill, North Carolina 27516, United States
  • Investigative Site US025
    Fargo, North Dakota 58103, United States
  • Investigative Site US015
    Bexley, Ohio 43209, United States
  • Investigative Site US044
    Cincinnati, Ohio 45219, United States
  • Investigative Site US008
    Columbus, Ohio 43230, United States
  • Investigative Site US031
    Mason, Ohio 45040, United States
  • Investigative Site US048
    Oklahoma City, Oklahoma 73118, United States
  • Investigative Site US043
    Danville, Pennsylvania 17822, United States
  • Investigative Site US056
    Philadelphia, Pennsylvania 19107, United States
  • Investigative Site US024
    Charleston, South Carolina 29425, United States
  • Investigative Site US041
    Myrtle Beach, South Carolina 29788, United States
  • Investigative Site US047
    Nashville, Tennessee 37215, United States
  • Investigative Site US062
    Dallas, Texas 75390, United States
  • Investigative Site US035
    El Paso, Texas 79902, United States
  • Investigative Site US032
    Frisco, Texas 75033, United States
  • Investigative Site US012
    Plano, Texas 75025, United States
  • Investigative Site US011
    San Antonio, Texas 78213, United States
  • Investigative Site US040
    Layton, Utah 84041, United States
  • Investigative Site US037
    Murray, Utah 84107, United States
  • Investigative Site US039
    Ogden, Utah 84405, United States
  • Investigative Site US058
    Seattle, Washington 98195, United States
  • Investigative Site BG002
    Sofia, 01407, Bulgaria
  • Investigative Site BG003
    Sofia, 01463, Bulgaria
  • Investigative Site CA004
    Calgary, Alberta T2J 7E1, Canada
  • Investigative Site CA003
    Calgary, Alberta T3E 0B2, Canada
  • Investigative Site CA009
    Ottawa, Ontario K1K 4L2, Canada
  • Investigative Site CA002
    Peterborough, Ontario K9J 5K2, Canada
  • Investigative Site CA001
    Richmond Hill, Ontario L4B 1L1, Canada
  • Investigative Site CA007
    Toronto, Ontario M3B 0A7, Canada
  • Investigative Site CA005
    Toronto, Ontario M4E 1R7, Canada
  • Investigative Site CA006
    Waterloo, Ontario N2J 1C4, Canada
  • Investigative Site CA008
    Sherbrooke, Quebec J1G 1X9, Canada
  • Investigative Site FR002
    Bordeaux, 33000, France
  • Investigative Site FR005
    Brest, 29609, France
  • Investigative Site FR004
    Nantes, 44093, France
  • Investigative Site FR003
    Nice, 06200, France
  • Investigative Site FR001
    Paris, 75010, France
  • Investigative Site DE006
    Berlin, 10117, Germany
  • Investigative Site DE005
    Berlin, 13595, Germany
  • Investigative Site DE002
    Bochum, 44791, Germany
  • Investigative Site DE004
    Darmstadt, 64283, Germany
  • Investigative Site DE001
    Dresden, 01307, Germany
  • Investigative Site DE003
    Erlangen, 91054, Germany
  • Investigative Site DE007
    Hamburg, 20246, Germany
  • Investigative Site DE008
    Lübeck, 23538, Germany
  • Investigative Site IT001
    Catania, 95123, Italy
  • Investigative Site IT005
    Cona, 44124, Italy
  • Investigative Site IT009
    Florence, 50122, Italy
  • Investigative Site IT003
    Milan, 20122, Italy
  • Investigative Site IT007
    Naples, 80131, Italy
  • Investigative Site IT006
    Roma, 00137, Italy
  • Investigative Site IT004
    Roma, 00144, Italy
  • Investigative Site IT002
    Rozzano, 20089, Italy
  • Investigative Site IT008
    Torino, 10126, Italy
  • Investigative Site PL002
    Lodz, 90-436, Poland
  • Investigative Site PL003
    Torun, 87-100, Poland
  • Investigative Site PL001
    Warsaw, 02-962, Poland
  • Investigative Site PL004
    Wroclaw, 54-239, Poland
  • Investigative Site ES004
    Alicante, 03010, Spain
  • Investigative Site ES005
    Badalona, 08916, Spain
  • Investigative Site ES003
    Barcelona, 08003, Spain
  • Investigative Site ES001
    Madrid, 28009, Spain

Showing the first 100 of 101 sites across 8 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Oct 2026, 16 months.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 6, 2025
StartActual
Jun 23, 2025
Primary completionActual
Oct 29, 2026
CompletionEst.
Jul 11, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 9, 2026→Oct 29, 2026 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Oct 9, 2026→Oct 29, 2026 (now actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06959225
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
May 6, 2025
Start date
Jun 23, 2025
Primary completion
Oct 29, 2026
Completion
Jul 11, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Incyte Study Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion